At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, from May 30 to June 3, the results of the Phase Ib/II clinical study of 9MW2821 in combination with ...

RVPH Open Label Extension Key Opinion Leader Event Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) held a key opinion ...

An analysis of the CALLA study shows that ctDNA is detected an average of 5.5 months before radiographic progression.

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Innovation in clinical diagnostics is accelerating, with breakthroughs that promise to make testing more precise, less invasive and more accessible. These advancements are expected not only to benefit ...

Highlights from the 2025 Global Equine Endocrinology Symposium included never-before-presented study results on insulin ...

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

Detection of cancer before a clinical diagnosis could give patients and caregivers more time for intervention and may lead to ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.